secondary progressive MS

Phase 1 trial of KYV-101 opening in progressive MS without relapses

Researchers at Stanford University have partnered with Kyverna Therapeutics to conduct an investigator-initiated clinical trial of the company’s cell-based therapy, KYV-101, in people with progressive forms of multiple sclerosis (MS) without relapses. The open-label Phase 1 trial (NCT06138132) will take place at the Stanford Multiple Sclerosis…

Stem cell therapy well tolerated in SPMS clinical trial

A novel therapy in which neural stem cells are injected into the brain was well tolerated by 15 people with secondary progressive multiple sclerosis (SPMS) in a pilot clinical trial. Participants’ disability levels and cognition, as well as markers of inflammation and nerve damage, all remained stable for up…

Progressive MS trial of vidofludimus calcium fully enrolled

A global Phase 2 clinical trial investigating the oral therapy vidofludimus calcium (IMU-838) in people with progressive forms of multiple sclerosis (MS) has reached full enrollment, the treatment’s developer, Immunic Therapeutics, reports. Called CALLIPER (NCT05054140), the trial is assessing whether the neuroprotective effects of vidofludimus calcium seen in…

More, earlier damage seen in primary progressive MS vs SPMS

People with primary progressive multiple sclerosis (MS) may experience more severe inflammatory activity and nerve damage early on in the course of their disease as compared with individuals who have secondary progressive MS, a new study indicates. The results also suggest that primary progressive MS patients tend to have…

All Quiet on the MS Front — Well, Nearly

Note: The second half of this column details digestive symptoms that may make readers uncomfortable.  In the five years that I’ve written this “irreverent journey with multiple sclerosis (MS),” quoting from my very own bio at the foot of this column, I think I’ve only covered this “quiet”…

Global Prevalence of SPMS Estimated, But Seen to Vary Widely

Worldwide, about 22 in every 100,000 people live with secondary progressive multiple sclerosis (SPMS), a review study analyzing data across various countries reported. Its researchers found substantial variability in SPMS rates country-by-country, with countries closer to the poles generally reporting higher prevalence than those near the equator. Rates also…

EMBOLD Study of ATA188 in Progressive MS Is Given Go-ahead

An independent committee of experts has recommended that the Phase 2 portion of the EMBOLD clinical trial continue as planned without a sample size adjustment, following an analysis of safety and effectiveness data. The trial is testing Atara Biotherapeutics‘ experimental medication ATA188 in progressive forms of multiple…

8 More SPMS Patients Cleared for Foralumab Nasal Spray Treatment

Based on findings from the first two secondary progressive multiple sclerosis (SPMS) patients given foralumab nasal spray, an experimental therapy, the U.S. Food and Drug Administration (FDA) has approved starting treatment in up to eight other patients under a special access program. Those enrolled in this intermediate-size expanded access…

The Captain and His No. 2

There I was, swinging away in my hoist at 9 p.m., though my swinging London of the 2020s wasn’t only 60 years later, it was also a lot, lot grimmer. My carer and maybe still wife, Jane, stood below in a controlled fury. If nothing else, she might…

Masitinib Slows Disability Progression in PPMS, Non-active SPMS

Masitinib, AB Science’s experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial. These findings, indicating that the trial met its main goal, support…

MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS

MediciNova is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. “Over the past quarter, we…

Mayzent Approved for Active Secondary Progressive MS in Scotland

The Scottish Medicines Consortium (SMC) has approved Mayzent (siponimod) for the treatment of active secondary progressive multiple sclerosis (SPMS) in Scotland. Mayzent, developed by Novartis, is a tablet taken once daily to counter a person’s disability progression. SPMS gradually develops from relapsing-remitting MS, and is…

#CMSC17 – Review Suggests Certain MS Patient Groups May Discontinue Disease-Modifying Treatments

Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after five years may safely discontinue their treatments, Canadian researchers at Vancouver’s University of British Columbia argue. Their Sanofi Genzyme-sponsored study, “When Should Disease-Modifying Treatments Be Discontinued in Patients with Multiple Sclerosis: An…

Mitoxantrone, a Drug for Progressive and Severe Relapsing MS, Linked to Colorectal Cancer Risk

Mitoxantrone,  a multiple sclerosis (MS)  drug that is already associated with a higher risk for leukemia and heart damage, may also raise a person’s risk of colorectal cancer, researchers at the University of Würzburg, in Germany, reported. If confirmed in larger studies, the findings indicate that colonoscopies should be conducted on MS patients after…

Anti-LINGO-1: All You Need to Know

Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what is Anti-LINGO-1? According to the MS Society, Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…